The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, but its position within the broader industry now presents questions about long-term gains. Generic versions are diminishing market share, causing worries that betting on companies heavily reliant to Viagra's once-dominant influence could be a speculative move